JGUA
HZNP

John G. Ullman & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

John G. Ullman & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-78,762
Closed -$9.11M – 184
2023
Q3 		$9.11M Sell
78,762
-950
-1% -$102K 1.49% 18
2023
Q2 		$8.2M Sell
79,712
-2,275
-3% -$240K 1.26% 20
2023
Q1 		$8.95M Sell
81,987
-1,375
-2% -$152K 1.39% 19
2022
Q4 		$9.49M Sell
83,362
-4,640
-5% -$385K 1.51% 17
2022
Q3 		$5.45M Buy
88,002
+2,500
+3% +$175K 0.95% 33
2022
Q2 		$6.82M Buy
85,502
+18,600
+28% +$1.76M 1.09% 29
2022
Q1 		$7.04M Sell
66,902
-1,625
-2% -$158K 0.98% 33
2021
Q4 		$7.38M Sell
68,527
-850
-1% -$92.7K 1.02% 33
2021
Q3 		$7.6M Sell
69,377
-767
-1% -$79.6K 1.03% 37
2021
Q2 		$6.57M Sell
70,144
-2,183
-3% -$201K 0.86% 37
2021
Q1 		$6.66M Sell
72,327
-3,200
-4% -$270K 0.89% 37
2020
Q4 		$5.53M Sell
75,527
-925
-1% -$68.8K 0.86% 42
2020
Q3 		$5.94M Sell
76,452
-400
-0.5% -$27.5K 1.23% 29
2020
Q2 		$4.27M Sell
76,852
-200
-0.3% -$8.56K 1.04% 30
2020
Q1 		$2.28M Sell
77,052
-1,300
-2% -$44K 0.61% 44
2019
Q4 		$2.84M Sell
78,352
-1,200
-2% -$36.8K 0.49% 58
2019
Q3 		$2.17M Buy
+79,552
New +$2.06M 0.39% 59

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

John G. Ullman & Associates's HZNP Position: Q4 2023 in Review

John G. Ullman & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 78,762 shares — an estimated $9.11M sold.

John G. Ullman & Associates first reported a position in HZNP in Q3 2019 and held it in 17 quarters. The position peaked at $9.49M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • John G. Ullman & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • John G. Ullman & Associates sold 78,762 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $9.11M.
  • John G. Ullman & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 17 quarters.
  • John G. Ullman & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $9.49M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on John G. Ullman & Associates's 13F filing for Q4 2023, filed 31 Jan 2024.